Bicara Therapeutics/$BCAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Ticker
$BCAX
Sector
Primary listing
Employees
103
Headquarters
Website
BCAX Metrics
BasicAdvanced
$1.3bn
-
-$2.80
-
-
Price and volume
Market cap
$1.3bn
52-week high
$24.25
52-week low
$8.48
Average daily volume
493k
Financial strength
Current ratio
13.851
Quick ratio
13.72
Long term debt to equity
0.059
Total debt to equity
0.28
Profitability
EBITDA (TTM)
-173.928
Effective tax rate (TTM)
-0.13%
Management effectiveness
Return on assets (TTM)
-21.09%
Return on equity (TTM)
-32.34%
Valuation
Price to book
2.55
Price to tangible book (TTM)
2.55
Price to free cash flow (TTM)
-9.649
Free cash flow yield (TTM)
-10.36%
Free cash flow per share (TTM)
-2.073
Growth
Earnings per share change (TTM)
-8.35%
BCAX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs